ELAN: Elanco Animal Health Incorporated Stock

by  •  • Comments Off on ELAN: Elanco Animal Health Incorporated Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 6,164.58
Enterprise Value ($M) 10,031.58
Book Value ($M) 6,523.00
Book Value / Share 13.20
Price / Book 0.95
NCAV ($M) -3,394.00
NCAV / Share -6.87
Price / NCAV -1.82

Profitability (mra)
Return on Invested Capital (ROIC) 0.02
Return on Assets (ROA) 0.01
Return on Equity (ROE) 0.03

Liquidity (mrq)
Quick Ratio 1.31
Current Ratio 2.55

Balance Sheet (mrq) ($M)
Current Assets 3,366.00
Assets 13,283.00
Liabilities 6,760.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
07-08 13G/A BlackRock, Inc. 4.70 -16.13
02-13 13G/A Dodge & Cox 17.00 -0.94
02-13 13G/A Vanguard Group Inc 10.04 0.33
02-12 13G/A Primecap Management Co/ca/ 10.27 -0.06

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-02-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 001-38661 Elan

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-31 673,129 5,343,879 12.60
2025-01-30 1,044,318 6,100,518 17.12
2025-01-29 833,452 4,120,777 20.23
2025-01-28 493,441 4,639,589 10.64
2025-01-27 733,364 7,625,983 9.62

(click for more detail)

Similar Companies
BHVN – Biohaven Ltd. BMY – Bristol-Myers Squibb Company
EBS – Emergent BioSolutions Inc. HYAC – Haymaker Acquisition Corp. 4
JNJ – Johnson & Johnson


Financial data and stock pages provided by
Fintel.io